ACKNOWLEDGMENTS
Johnson & Johnson, and Amgen, Cancer
CANCER
The authors thank all patients, treating physicians, and research support staff at all participating centers.E.A.D.: conceptualization, methodology, formal analysis, investigation, writing—original draft, visualization, and project administration. P.J.N.: conceptualization, validation, methodology, formal analysis, resources, writing—original draft, supervision, project administration, and funding acquisition. G.A.P.H.: conceptualization, methodology, resources, writing—review and editing, project administration, and funding acquisition. R.R.B.: methodology and writing—review and editing. E.M.-K.K.: conceptualization, methodology, formal analysis, data curation, writing—review and editing, and project administration. A.G.H.R.: conceptualization, methodology, data curation, writing—review and editing, and project administration. H.P.: conceptualization, methodology, software, writing—review, and editing. Å.B.: resources and writing—review and editing. A.C.: resources and writing—review and editing. R.M.P.H.C.: resources and writing—review and editing. M.P.H.: resources and writing—review and editing. J.C.: resources and writing—review and editing. I.E.: resources and writing—review and editing. C.A.M.M: conceptualization, methodology, resources, writing—review and editing, project administration, and funding acquisition. C.J.H.v.d.V.: conceptualization, methodology, resources, writing—review and editing, project administration, and funding acquisition. B.G.: conceptualization, methodology, resources, writing—review and editing, project administration, and funding acquisition. B.v.E: conceptualization, validation, methodology, formal analysis, resources, writing—original draft, supervision, project administration, and funding acquisition.B.G. and B.v.E. shared last authorship.Funding for this study was acquired from the Dutch Cancer Foundation (CKS-2011-4997); the Swedish Cancer Society; the Swedish Research Council (project number K2014-99X-22481-01-3); the Spanish Ministry of Economy and Competitiveness through the Carlos III Health Institute EC11-423, and by the Spanish Clinical Research Network (SCReN-PT13/0002/0031; PT17/0017/0003; cofinanced by European Regional Development Fund “A way to make Europe”).P.J.N. reports honoraria from Ethicon, Johnson & Johnson, and Amgen. GAPH reports consulting fees from Roche, MSD, Amgen, and Novartis; consulting fees and research support to their institution from Bristol Myers Squibb; and research support to their institution from Seerave Foundation. A.G.H.R. and C.J.H.v.d.V. were partially funded by the EU’s Horizon 2020 research and innovation program under a Marie SkłodowskaCurie grant award (H2020MSCAITN2019, grant agreement number 857894; project acronym: CAST). M.P.H. reports consulting fees from MSD. J.C. reports consulting fees, travel expenses, and research support to their institution from Pfizer, Ipsen, and Eisai; consulting fees and research support to their institution from Bayer, Novartis, and Advanced Accelerator Applications; consulting fees from Sanofi, Exelixis, and Merck Serono; and research support to their institution from AstraZeneca. B.G. reports research support from the Swedish Cancer Society. The remaining authors report no conflicts of interest.Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, 